Application Note: Characterization of Anti-HER2 Antibodies Using iQue® & Octet® Platforms
Authors: Kirsty McBain, Daryl Cole, and Nicola Bevan | Last updated: 11/1/2022
Overview
For continued growth and diversification of the monoclonal antibody (mAb) therapeutic market we need robust, high-throughput techniques for screening and profiling drug candidates. Here we analyze anti-HER2 mAbs to demonstrate the power of a combined iQue® Advanced Flow Cytometry and Octet® BLI Label-Free Detection approach for antibody characterization. iQue® delivers rapid, live cell-based assessment of binding, competition and function, while Octet determines binding kinetics and evaluates post-translational modifications.
- Document type: Application Note
- Page count: 1
- Read time: 6 minutes
Key Takeaways:
- Discover a robust and high-throughput method for screening and characterizing mAb drug candidates
- Identify mAbs that compete for epitope binding
- Rank antibodies based on glycosylation status
- Analyze Fc receptor function in immune cell co-culture
- Assess binding and specificity on live cells
This Resource is Designed for:
- Drug developers
- Analytical scientists
- R&D scientists
Applications Supported:
- Biotherapeutic discovery and development
- Molecule development
- Antibody discovery and development
A workflow diagram highlighting the complementaryiQue® and Octet® systems for mAb screening characterization
